Condition: Glioma · Sponsor: Plus Therapeutics
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.
This description comes directly from the study's public registry record.
Rachael Hershey · 1(210) 791-8723 · patients@respect-trials.com
Andrew Brenner, PhD · 1(210) 791-8723 · patients@respect-trials.com
Always discuss trial participation with your own doctor first.
| Northshore University Hospital | Manhasset, New York, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| The Cancer Therapy and Research Center at UTHSCSA | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01906385